Eli Lilly recently presented updated safety and tolerability data for its next-generation obesity medication, retatrutide.
This information was shared during the annual meeting of the American Diabetes Association, highlighting the company's ongoing research efforts.
The findings may play a significant role in the future development and approval of retatrutide as a treatment option for obesity.